SAN DIEGO , April 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today
SAN DIEGO , April 20, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of
Target Selector™ assay kits enable assay developers to leverage Biocept's patented, high-sensitivity technology for the detection of key actional oncogene mutations from both tissue biopsies and blood for liquid biopsy uses SAN DIEGO , April 28, 2020 /PRNewswire/ -- Biocept, Inc .
SAN DIEGO , April 29, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
Revenues of $1.4 million increased 41%, revenue per accession increased 27% Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO , May 13, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically
Target Selector™ molecular assay kits are research-use-only (RUO) and offer superior sensitivity compared to NGS-based biomarker analysis for the detection of key actionable oncogene mutations SAN DIEGO , May 14, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of
SAN DIEGO , May 20, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W.
Target Selector™ platform shown to be potentially more sensitive than standard-of-care cytology in detecting mutations of brain metastases in cerebrospinal fluid SAN DIEGO , May 29, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed
SAN DIEGO , June 5, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate
SAN DIEGO , June 22, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000
